Literature DB >> 19043810

Adhesion-dependent growth of primary adult T cell leukemia cells with down-regulation of HTLV-I p40Tax protein: a novel in vitro model of the growth of acute ATL cells.

Kazuhiro Nagai1, Itsuro Jinnai2, Tomoko Hata3, Tetsuya Usui4, Daisuke Sasaki4, Kunihiro Tsukasaki3, Kazuyuki Sugahara4, Yoshitaka Hishikawa5, Yasuaki Yamada4, Yuetsu Tanaka6, Takehiko Koji5, Hiroyuki Mano7, Shimeru Kamihira8,4, Masao Tomonaga3.   

Abstract

In order to better understand the biology of adult T cell leukemia (ATL), we aimed to establish a novel method, which allows the primary growth of ATL cells using a co-culture system with murine bone marrow-derived stromal cells, MS-5. ATL cells grew in close contact with MS-5 layers and formed so-called "cobblestone areas" (CAs) without the addition of IL-2. In clinical samples, eight of ten (80.0%) cases of acute or lymphoma type ATL cells formed CAs. The frequency of CA forming cells in ATL cells ranged from 0.03 to 1.04%. The morphology, immunophenotyping, and DNA analysis indicated that cells composing CA were compatible with ATL cells, and clonally identical to primary CD4-positive ATL cells. Furthermore, in ATL cells composing CA, the expression of p40Tax was down-regulated in transcriptional and translational level, while that of HTLV-I basic leucine zipper factor (HBZ) gene was comparable to the level of primary ATL cells, resembling expression pattern of proviral genes in in vivo ATL cells. By microarray analysis, several genes which coded products involved in cell-cell interaction, and cellular survival and proliferation, were differentially expressed in ATL cells composing CA compared with primary samples. In conclusion, our co-culture system allows for the first time the growth of primary ATL cells in vitro, and might be useful as an in vitro assay for biological and clinical studies to develop molecular targeting drugs against ATL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043810     DOI: 10.1007/s12185-008-0207-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  59 in total

1.  Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count.

Authors:  S Kamihira; N Dateki; K Sugahara; T Hayashi; H Harasawa; S Minami; Y Hirakata; Y Yamada
Journal:  Clin Lab Haematol       Date:  2003-04

2.  Detection of mRNA for the tax1/rex1 gene of human T-cell leukemia virus type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction.

Authors:  T Kinoshita; M Shimoyama; K Tobinai; M Ito; S Ito; S Ikeda; K Tajima; K Shimotohno; T Sugimura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

3.  Detection of human T lymphotrophic virus type I (HTLV-I) DNA and mRNA in individual cells by polymerase chain reaction (PCR) in situ hybridization (ISH) and reverse transcription (RT)-PCR ISH.

Authors:  K Ohshima; K Hashimoto; S Izumo; J Suzumiya; M Kikuchi
Journal:  Hematol Oncol       Date:  1996-06       Impact factor: 5.271

4.  Heavy metal intensification of DAB-based HRP reaction product.

Authors:  J C Adams
Journal:  J Histochem Cytochem       Date:  1981-06       Impact factor: 2.479

5.  A genomic analysis of adult T-cell leukemia.

Authors:  Y L Choi; K Tsukasaki; M C O'Neill; Y Yamada; Y Onimaru; K Matsumoto; J Ohashi; Y Yamashita; S Tsutsumi; R Kaneda; S Takada; H Aburatani; S Kamihira; T Nakamura; M Tomonaga; H Mano
Journal:  Oncogene       Date:  2006-08-14       Impact factor: 9.867

6.  Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease.

Authors:  M Yoshida; M Seiki; K Yamaguchi; K Takatsuki
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

7.  Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells.

Authors:  T Uchiyama; T Hori; M Tsudo; Y Wano; H Umadome; S Tamori; J Yodoi; M Maeda; H Sawami; H Uchino
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

8.  Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma.

Authors:  K Tsukasaki; S Ikeda; K Murata; T Maeda; S Atogami; H Sohda; S Momita; T Jubashi; Y Yamada; M Mine
Journal:  Leuk Res       Date:  1993-02       Impact factor: 3.156

9.  The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers.

Authors:  Michelle T Paulsen; Adrienne M Starks; Frederick A Derheimer; Sheela Hanasoge; Liwu Li; Jack E Dixon; Mats Ljungman
Journal:  Mol Cancer       Date:  2006-06-19       Impact factor: 27.401

10.  Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells.

Authors:  Y Tanaka; K Kimata; A Wake; S Mine; I Morimoto; N Yamakawa; H Habuchi; S Ashikari; H Yamamoto; K Sakurai; K Yoshida; S Suzuki; S Eto
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells.

Authors:  Toshiki Watanabe
Journal:  Blood       Date:  2017-01-23       Impact factor: 22.113

2.  Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon.

Authors:  Shuichi Kinpara; Atsuhiko Hasegawa; Atae Utsunomiya; Hironori Nishitsuji; Hiroyuki Furukawa; Takao Masuda; Mari Kannagi
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

3.  A Preclinical Model for the ATLL Lymphoma Subtype With Insights Into the Role of Microenvironment in HTLV-1-Mediated Lymphomagenesis.

Authors:  Mattia Vicario; Adriana Mattiolo; Barbara Montini; Maria Assunta Piano; Ilaria Cavallari; Alberto Amadori; Luigi Chieco-Bianchi; Maria Luisa Calabrò
Journal:  Front Microbiol       Date:  2018-06-13       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.